The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study.
Gláucio Silva Camargos, Geraldo Magela De Faria Júnior, Marcelo Lourenço, Gerardo Maria De Araújo Filho
Frontiers in psychiatry January 1, 2026 DOI: 10.3389/fpsyt.2026.1726909 via PubMed
Summary
AI-generated from the abstractOver six months, depressive symptoms decreased significantly in 280 adults with depressive, anxiety, or substance use disorders after ritualistic ayahuasca use combined with psychotherapeutic support. Scores on the Montgomery-Åsberg Depression Rating Scale dropped shortly after the intervention and remained lower for up to 180 days, though individual responses varied. The findings suggest that ayahuasca-assisted therapy can reduce depression and anxiety and may help treat substance dependence. Variability in outcomes indicates that psychodynamic factors, including integration of the psychedelic experience and ongoing therapeutic support, are crucial for effectiveness. The work supports developing personalized psychedelic-assisted treatment protocols for complex psychiatric conditions.
Study at a glance
| Characteristics | Longitudinal observational study Peer reviewed |
|---|---|
| Sample size | 280 |
| Population | Adults with depressive disorders, anxiety disorders, or substance use disorders treated at clinics in northwestern São Paulo, Brazil |
| Intervention | Ayahuasca |
| Duration | Six-month follow-up after the ayahuasca intervention |
| Topics | Ayahuasca |
| Keywords | Mental disorders Psychedelics Psychotherapy Resistant depression |
| Key finding | Ayahuasca combined with psychotherapeutic support was associated with significant reductions in depressive symptoms sustained for up to 180 days, though individual responses varied. |
Abstract
This longitudinal observational study evaluated changes in depressive symptoms associated with ritualistic ayahuasca use in patients diagnosed with depressive disorders, as well as depressive burden in individuals with anxiety and substance use disorders. The research was conducted with 280 adults treated at clinics in the northwestern region of the state of São Paulo, under the jurisdiction of Regional Health Division XV (DRS XV), which covers a population of over 2 million inhabitants. Participants were assessed at six different time points over a six-month follow-up period after the ayahuasca intervention, with depressive symptoms measured using the Montgomery-Åsberg Depression Rating Scale (MADRS). The results indicate a significant reduction in depression scores shortly after the intervention, with improvements sustained for up to 180 days, though individual responses varied. The analysis reveals that ayahuasca, when combined with psychotherapeutic support, can provide significant benefits in reducing symptoms of depression and anxiety, and also shows potential in the treatment of substance dependence. We concluded that the final variability in responses suggests that psychodynamic and clinical factors, such as the integration of the psychedelic experience and therapeutic support, play a crucial role in treatment effectiveness. This study contributes to the consolidation of psychedelic-assisted therapeutic protocols, highlighting the importance of continuous and personalized follow-up in the treatment of complex psychiatric conditions.